| Grab Sources And More Here: ACON Website. ACON Presentation. -----
And as I mentioned above, (Nasdaq: ACON) has multiple potential catalysts of focus. Take a look:
#1. ACON Potential Catalyst - A Very Small Float Could Create An Environment Ripe For Volatility.
According to the Yahoo Finance website, ACON has a tiny low float.
In fact, the website reports this profile to have approximately 671.34k shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
Could even more positive company news towards the end of 2025 provide a breakout spark when paired with this volatility potential? -----
#2. ACON Potential Catalyst - A Major Analyst $23 Target Suggests Triple-Digit Potential Upside.
Last month, Ascendiant Capital Markets' analyst Lucas Warn released an update note on Aclarion, Inc. (Nasdaq: ACON) with a $23.00 price target.
From Wednesday's closing valuation, that target provides ACON with a potential upside of over 225%!
Here are some highlights from the report:
Raising 12-month price target to $23.00 (from $22.00): We are raising our 12- month target to $23.00 (from $22), based on a NPV analysis. Our new target of $23.00 represents 2.7x upside from the current share price. With net cash per share of $17, the st-ock resembles a call on the commercialization of Nociscan, a process which is well underway. Risks to our thesis include slower than expected traction with surgeons and higher than expected marketing and administrative expenses. -----
#3. ACON Potential Catalyst - A Key Corporate Update Hints At Key Catalyst Potential Growing On The Horizon.
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
- Debt-free balance sheet with $13.3Mn in cash... providing strategic flexibility for continued commercial growth
- Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets
- CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues
...
BROOMFIELD, Colo., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage heal-thcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued its Q3 2025 corporate update highlighting its strong financial position, accelerating market adoption, and continued progress in the pivotal CLARITY trial.
Market Adoption & Growth Momentum
Nociscan scan volumes increased +89% year-over-year in Q3 – marking the third consecutive quarter of accelerating growth across U.S., U.K., and E.U. sites.
Three straight quarters of record utilization underscore growing physician adoption and commercial traction.
MR Spectroscopy and biomarker technology featured at the International Society of Pain and Neuroscience (ISPN) annual meeting in London validating the importance of disc chemistry as a key biomarker for chronic low back pain diagnosis.
...
Commercial expansion strategy on track to drive new revenue channels and strengthen global brand visibility in 2026.
Key Value Catalyst: CLARITY Trial Progress & AI Algorithm Validation
CLARITY pivotal trial advancing on schedule – first patients enrolled at UHealth-University of Miami Health System and the Miller School of Medicine, advancing progression towards full enrollment of CLARITY patients by Q4 2026.
Trial designed to quantify the clinical value of integrating Nociscan data into surgical planning, targeting outcomes that significantly exceed current ~54% industry benchmarks.
...
“We are executing on our key milestones– expanding adoption, accelerating Nociscan growth, and advancing the CLARITY trial on time,” said Brent Ness, Chief Executive Officer of Aclarion. “Greg’s addition as CFO strengthens our leadership team at a pivotal inflection point. With a debt-free balance sheet, expanding data pipeline, and growing commercial traction, Aclarion is positioned to create meaningful long-term value for patients and shareholders alike.”
...
Read the full article here. -----
#4. ACON Potential Catalyst - The Company Earns An "Incredible Honor" As They're Named A "Rising Star."
Aclarion Wi-ns “Rising Star” at 2025 Digital Heal-th Hub Foundation: Digital Heal-th A-wards at HLTH
Company previously announced it was selected as a finalist from more than 1,800 submissions
A-ward w-i-n underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain
BROOMFIELD, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a heal-thcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced it was named a Rising Star in the Clinical Diagnostic Device category during the 2025 Digital Health Hub Foundation: Digital Heal-th A-wards at HLTH.
Rising Star
The Digital Health A-wards are held annually and celebrates advancements in the digital heal-th industry. The Rising Star track highlights emerging digital heal-th companies that show exceptional potential and clinical impact. Chief Strategy Officer Ryan Bond accepted the a-ward on behalf of Aclarion, recognizing the company as a next-generation innovator making significant changes through technology for patients with chronic low back pain.
“It’s an incredible honor to be recognized as a Rising Star and to be part of the Digital Health Awards at HLTH ecosystem that is shaping the future of digital heal-th,” said Ryan Bond, Chief Strategy Officer of Aclarion. “This a-ward underscores our team’s commitment to advancing objective, noninvasive information that helps physicians ‘see pain’ and make better treatment decisions for the millions suffering from chronic low back pain worldwide.”
...
Read the full article here. -----
#5. ACON Potential Catalyst - Two Recent Appointments Hope To Drive Commercial Efforts And Market Expansion.
Over the last month, ACON has made two key appointments:
12/2/25: Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
11/5/25: Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
Could these actions lead (Nasdaq: ACON) to strengthen their commercial execution and market growth? -----
(Nasdaq: ACON) Recap - These 5 Potential Catalysts Are On Watch
#1. A Very Small Float Could Create An Environment Ripe For Volatility.
#2. A Major Analyst $23 Target Suggests Triple-Digit Potential Upside.
#3. A Key Corporate Update Hints At Key Catalyst Potential Growing On The Horizon.
#4. The Company Earns An "Incredible Honor" As They're Named A "Rising Star."
#5. Two Recent Appointments Hope To Drive Commercial Efforts And Market Expansion. -----
Now officially underway: coverage is kicked-off on Aclarion, Inc. (Nasdaq: ACON).
Be on the lookout for updates coming out soon. Talk shortly.
Sincerely, Kai Parker StockWireNews
Sources: (1) Ravindra VM, Global Spine Journal (2018) 8(8): 784-794 (2) Wei J, Song Y, et al. Comparison of artificial total disc replacement versus fusion for lumbar disc disease: a meta-analysis of randomized controlled trials. Int Orthop. 2013; 37(7):1315-1325 (3) Ibrahim T, Tieyjeh IM, et al. Surgical versus nonsurgical treatment of chronic low back pain: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/03/2025 and ending on 12/04/2025 to publicly disseminate information about (ACON:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (ACON:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/acon-qprwm/#details | 
0 التعليقات:
إرسال تعليق